Showing results (1911-1920 of 2,338) with videos related to

Sort By:
Pageof 234
The Journal of Rheumatology|July 6, 2007
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA studyLuana Mancarella, Francesca Bobbio-Pallavicini, Fulvia Ceccarelli, et al.
Therapeutic Advances in Musculoskeletal Disease|September 16, 2021
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA NetworkCarla Gaggiano, Donato Rigante, José Hernández-Rodríguez, et al.
Scientific Reports|October 30, 2025
Pain catastrophizing and its domains significantly impact rheumatoid arthritis disease activityDamiano Currado, Lyubomyra Kun, Francesca Saracino, et al.
Journal of Nephrology|January 24, 2022
SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological responseFederico Alberici, Stefania Affatato, Daniele Moratto, et al.
Annals of the Rheumatic Diseases|May 15, 2001
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexesG Valentini, A Della Rossa, S Bombardieri, et al.
Arthritis Research & Therapy|September 18, 2024
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) studyDamiano Currado, Francesca Saracino, Piero Ruscitti, et al.
International Journal of Biological Sciences|July 29, 2026
In vivo delivery strategies for therapeutic CRISPR genome editingLeonardo Martin, Jure Bohinc, Alessandra Recchia, et al.
Annals of the Rheumatic Diseases|October 8, 2021
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19Alessia Alunno, Aurélie Najm, Pedro M Machado, et al.
Frontiers in Medicine|July 26, 2021
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA NetworkAntonio Vitale, Laura Obici, Marco Cattalini, et al.
Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.
Pageof 234